Lilly lifts 2026 outlook after strong Q1 2026 results and Foundayo FDA approval
Lilly posted a 56% YoY surge in Q1 2026 revenue to $19.8B, with GAAP EPS of $8.26 and non-GAAP EPS of $8.55, driven by volume growth despite lower realized prices; raised full-year revenue guidance to $82–$85B and non-GAAP EPS to $35.50–$37.00; highlighted regulatory progress including FDA approval of Foundayo (orforglipron) for obesity, plus pipeline advances across multiple programs; announced four acquisitions (Orna Therapeutics, Centessa, Kelonia, Ajax Therapeutics); and plans an Investment Community Meeting for December 7, 2026.